Galectin-1 inhibition (novel therapeutic target in MPN)
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-06-23 — Galectin-1 Fuels Monocyte Hyperinflammation and Represents a Novel Therapeutic Target in Myeloproliferative Neoplasms.: Preclinical study (scRNA-seq, CyTOF, in vitro assays, and MPLW515L mouse model) shows LGALS1 is enriched in MPN monocytes and drives hyperinflammation via TLR4–NF-κB signaling; genetic and pharmacologic inhibition reduced splenomegaly, leukocytosis, and thrombosis in vivo. (novelty: 5)
Open questions
Related
Contributing findings
Galectin-1 Fuels Monocyte Hyperinflammation and Represents a Novel Therapeutic Target in Myeloproliferative Neoplasms.
23-jun-2026
novelty 5
per-area 5
introduces